US Stock MarketDetailed Quotes
NTLA Intellia Therapeutics
- 16.650
- -0.850-4.86%
Close Nov 12 16:00 ET
- 16.800
- +0.150+0.90%
Post 19:11 ET
1.70BMarket Cap-3055P/E (TTM)
17.240High16.360Low2.64MVolume17.150Open17.500Pre Close44.04MTurnover2.62%Turnover RatioLossP/E (Static)101.85MShares34.87052wk High1.76P/B1.67BFloat Cap13.95052wk Low--Dividend TTM100.57MShs Float202.730Historical High--Div YieldTTM5.03%Amplitude9.180Historical Low16.687Avg Price1Lot Size
About Intellia Therapeutics Company
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Company Profile
SymbolNTLA
Company NameIntellia Therapeutics
Listing DateMay 6, 2016
Issue Price18.00
Founded2014
CEODr. John M. Leonard, M.D.
MarketNASDAQ
Employees526
Fiscal Year Ends12-31
Address40 Erie Street,Suite 130
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139
Phone1-857-285-6200
Websitehttp://www.intelliatx.com
Company Executives
- Name
- Position
- Salary
- Dr. John M. Leonard, M.D.
- Director, President and Chief Executive Officer
- 11.66M
- Dr. David Lebwohl, M.D.
- Executive Vice President and Chief Medical Officer
- 4.26M
- Edward J. Dulac, III
- Treasurer, Executive Vice President and Chief Financial Officer
- --
- Dr. Laura Sepp-Lorenzino, PhD
- Executive Vice President and Chief Scientific Officer
- 4.19M
- Eliana Clark
- Executive Vice President and Chief Technology Officer
- --
- Derek Hicks
- Executive Vice President and Chief Business Officer
- --
- James Basta, J.D.
- Executive Vice President, General Counsel and Corporate Secretary
- 3.99M
- Dr. Frank Verwiel, M.B.A.,M.D.
- Chairman of the Board
- 499.94K
- Muna Bhanji, Ph.
- Independent Director
- 455.25K
- William J. Chase
- Independent Director
- 996.21K
- Dr. Fred E. Cohen, D.Phil.,F.A.C.P.,M.D.
- Independent Director
- 452.44K
- Brian Goff
- Independent Director
- --
- Dr. Jesse Goodman, M.D.,M.P.H.
- Independent Director
- 449.94K
- Dr. Georgia Keresty, M.P.H.,PhD
- Independent Director
- 454.94K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
